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Abstract
Background: In the ovary, metastatic malignant melanoma may be confused with primary malignant melanoma
and presents a diagnosis challenge. Most cases are associated with disseminated diseases and poor prognosis. We
present this case report of a metastatic ovarian malignant melanoma simulating primary ovarian cancer.
Case report: A 45-year-old premenopausal woman was incidentally found to have an abdominal mass, 3 years after
removal of a cutaneous melanoma lesion. Ultrasound and CT scan revealed left two solid masses, which were found to
be an ovarian tumor at laparotomy. Left oophorectomy was performed. Histopathology and immunohistochemistry
showed melanoma metastasis to the ovary. Nine months later, the patient developed epilepsy and confusion. Magnetic
Resonance Imaging showed unique Wright frontal lobe lesion. She underwent stereotactic radio surgery and
dacarbazine monotherapy. For months later, the patient is died from disseminate disease progression.
Conclusion: Ovarian metastasis is an unusual presentation of cutaneous melanoma and the prognosis was dismal.
As illustrated by this case report, a differential diagnosis of a metastatic malignant melanoma must be considered.
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Introduction
The ovary is a frequent site of secondary spread from
extra-ovarian malignancies. Approximately 6-7% of the
patients presenting with suspected ovarian neoplasm
will prove to suffer from metastatic disease to the ovary
(1). Ovarian involvement by metastatic malignant mela-
noma is relatively uncommon and it is rare for mela-
noma to present clinically as an ovarian mass (2).
Solitary metastatic malignant melanoma to the ovary
may be confused with primary ovarian carcinoma. We
present this case report of metastatic ovarian malignant
melanoma simulating primary ovarian cancer.
Case report
In February 2010, a 45 years old premenopausal female
patient presented to us because acute pelvic pain in
relation with left ovarian mass. She gave no significant
gynecologic history. Abdominal and gynaecologic exam
disclosed left adnexal mass. Abdominal ultrasound com-
pleted with computed tomography (CT) scan revealed
two solid irregular masses measuring respectively 84 ×
46 mm, 45 × 34 mm, located centrally in the pelvis and
appearing to originate from the left side of the uterus.
Thorax (CT) scan and biologic laboratory investigations
were normal. The tumor marker, CA125, and levels of
CEA (carcinoembryonic antigen), AFP (alpha feto-pro-
tein) and beta-HCG (human chorionic gonadotrophin)
were normal. Previous history revealed a management
for a left plantar melanoma with palpable inguinal
lymph node without skip metastasis in December 2006.
Preoperative thoraco-abdominal and pelvic CT scan and
cerebral magnetic resonance imaging were normal.
Local excision lesion and elective inguinal lymph node
dissection were performed. Histopathology study
showed a superficial spreading melanoma with a nodular
phase growth pattern, breslow index 1,7 mm and Clark’s
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nodes dissected involved by metastatic melanoma. The
patient received adjuvant interferon alpha high dose for
eighteen months at medical oncology department. Fol-
low-up of the patient for the ensuing 3 years was with-
out any signs of recurrence. At laparotomy, a left
ovarian mass measuring 15 cm with an intact and
smooth capsule without adhesions to its surroundings
was discovered, whereas the right ovary and uterus
grossly appeared normal. Infracolic-omentum and peri-
t o n e a ls u r f a c ew e r ef r e eo fp e r i t o n e a ln o d u l e .L e f ts a l -
pingo-oophorectomy, right ovarian biopsy and uterine
biopsy via hysteroscopy were performed. Preleved tissue
was sends for frozen section examination. Histopathol-
ogy analysis of left ovarian mass objective a surgical spe-
c i m e nm e a s u r e d1 1b y9 . 5b y5c ma n dw e i g h e d3 2 0g .
Cut surface showed a multilocular cyst containing white
and cerebriform intracystic vegetations, with necrotic
hemorrhagic foci. The neoplasm formed diffuse sheets.
The fragments presented a diffuse infiltrate, masking the
normal tissue. This infiltrate consisted of a monomor-
phous proliferation of large cells, with an abundant pale
or eosinophilic cytoplasm. The nuclei were large round
or oval, and contained prominent nucleoli. Mitotic fig-
ures were rare. In many places, the tumour had been
destroyed by large areas of ischemic necrosis. The pro-
liferation was supported by a thin delicate fibro vascular
stroma. (Figure 1). Right ovarian and uterine biopsies
were intact. No melanin pigment was identified in the
tumor Cells. In the immunochemistry, Inhibine, CD99,
EMA, chromogranin, synaptophysin were negative; the
tumour cells strongly expressed PS100 and Melan A
(Figure 2A) HMB45 (Figure 2B) was observed in some
cells suggesting the diagnosis of metastatic ovarian ame-
lanic melanoma. Postoperative Thoracoabdominopelvien
CT scan was normal. Dacarbazine was proposed for
patient but she refused to receive it. After nine month
of pelvic surgery and disease stabilization, the patient
d e v e l o p e dc o n f u s i o na n de p i l e p s y .M a g n e t i cR e s o n a n c e
Imaging showed a unique brain metastasis lesion in the
Wright frontal lobe. She underwent stereotactic radio
surgery followed by Dacarbazine chemotherapy. The
patient died 4 months later.
Discussion
Melanoma affects usually the skin, adrenal glands and
ocular choroids with frequent sites of metastasis to the
skin, brain and lung and rarely to the ovary [1]. How-
ever, once the diagnosis of malignant melanoma of the
ovary has been established; the distinction of a primary
ovarian malignant melanoma from a metastatic tumor
must be made. Some authors [2,3] have restricted the
diagnosis of primary ovarian malignant melanoma to
those cases with no history of malignant melanoma at
any other site, where the tumor is confined to the ovary,
and where it arises in association with ovarian cystic ter-
atomas. Metastatic ovarian malignant melanomas are
more common than primary ovarian malignant melano-
mas; to date, about 77 cases of malignant melanoma
metastatic to the ovary [4-7] compared to only about 31
cases of primary ovarian malignant melanoma including
a compilation of 20 cases and individual case reports
[8-11] have been reported in the world literature.
Although approximately 20% of patients dying of malig-
nant melanoma have ovarian involvement at postmor-
tem examination, the diagnosis of ovarian malignant
melanoma is seldom made before autopsy [12]. This is
because most of these patients have multiorgan metas-
tases so the involvement of the ovary is not clinically
A B
Figure 1 Diffuse pattern of round cells. (A) contains abundant
cytoplasm, round to ovoid nucleus and prominent nucleoli (B). A:
original magnification × 40 H&E. B: original magnification × 200
H&E.
B A
Figure 2 A: PS100 is strongly expressed in both the nucleus
and the cytoplasm. Original magnification × 400 (PS100) B:
Immunostain for Melan A shows a diffuse, intensively cytoplasmic
positive reaction. Original magnification × 200 (Melan A)
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and sufficiently symptomatic to be diagnosed in living
patients. The time interval between the diagnosis of the
primary melanoma and ovarian metastasis has ranged
from months up to 18 years [13]. Our patient had an
intermediate, stage III melanoma, thus a 36% risk of
death at 10 years [14]. She developed ovarian mass
three years after melanoma diagnosis. Ovarian metas-
tases from melanoma are mostly unilateral [13], as in
our patient. Women of reproductive age are more prone
to metastatic ovarian involvement, which may be attrib-
uted to the higher blood flow to the premenopausal
ovary [12]. The extremities are the most frequent pri-
mary localization of melanoma, secondarily involving
the ovaries [13], as in our patient. Metastatic melanoma
to the ovary can mimic a primary ovarian malignancy
and may pose a diagnostic challenge. The majority of
ovarian metastasis from melanoma published so far has
been almost invariably diagnosed following surgical
treatment [4,13,15,16]. Levels of tumor markers are non
discriminatory and Ultrasound and CT scan were unable
to characterize the lesion as in our patient [15]. How-
ever Magnetic resonance imaging of the lesion can raise
suspicion of its nature because of a hyper-intense signal
in T1-weighted images. This hyper-intense signal is
related to the amount of melanin in the lesion and is
finally present in about a third of cases [15,16]. In our
patient, the possibility of the cutaneous melanoma
metastasizing to the ovary was not considered being
very rare and MRI was not performed. The pathological
diagnosis is also difficult, since the morphology of the
lesion is often nonspecific. An achromic or poorly pig-
mented lesion often leads to several biopsies before the
tumor is clearly defined. Diagnostic difficulties also arise
histologically as the tumors do not have a consistent
appearance and they can be mistaken for germ cell and
sex cord stromal tumors or granulosa tumor [13].
Hence, definite diagnosis relies on immunohistochemis-
try. S-100 is expressed in both the nucleus and the cyto-
plasm and has been found to be the most sensitive
marker, present in 95% of cases [3,5-7]. HMB-45 and
Melan A are expressed in the cytoplasm. In our
patient’s, history of cutaneous melanoma, the absence of
cystic teratomas lesion and tumor positive stain for
PS100 and Melan A markers (Figure 2) and negative
stain for of alpha-inhibin and CD99 confirmed the diag-
nosis of metastatic ovarian melanoma. The management
of ovarian tumor is surgical, with removal of the tumor
and evaluation for local, regional and distant spread.
Initial staging should evaluate thoroughly disease extent
and obtain pathologic diagnosis to guide further treat-
ment. Metastatic melanoma is associated with poor
prognosis with 11% 5-year survival [14]. Surgical treat-
ment for abdominal metastases of melanoma in one
report significantly prolonged survival; however com-
plete resection was only possible in one-third of the
patients [17]. Unilateral salpingo-oophorectomy has
been proposed as an appropriate treatment for meta-
static melanoma involving the ovary, if there is no evi-
dence of controlateral ovarian involvement or extra
ovarian spread [4,12]. In such cases of apparently resect-
able metastatic disease, preoperative screening for meta-
static disease in other sites is crucial, either with
conventional imaging or with PET scanning [18]. In dis-
seminated diseases, chemotherapy (single-agent or com-
bined) generally only yields a response rate of up to
25%. Though early studies of bio-chemotherapy and
immunotherapy were promising, most randomized trials
have failed to demonstrate a significant increase in
response rate or overall survival.. More targeted
approaches that capitalize on recent advances in our
understanding of melanoma pathogenesis have emerged.
Pro-apoptotic agents ‘Oblimersen’, an antisense inhibitor
of Bcl-2, and ‘Sorafenib’, an orally active small molecule
inhibitor of wild type and mutant BRAF or PLX4032 a
potent inhibitor of BRAF with the V600E mutation are
at the forefront of novel therapies developed for
advanced metastatic disease [19,20]. In our case the no
evidence of right lesion and abdominal spread, left uni-
lateral oophorectomy was performed without adjuvant
chemotherapy. The patient had a good postoperative
recovery with good health at nine months. She devel-
oped unique cerebral metastases lesion treated with
radio surgery followed by dacarbazine. 4 months later,
the patients died from disseminate disease progression.
Conclusion
In conclusion, this case illustrate that ovarian melanoma
is a rare disease, associated with a poor prognosis. Also
imaging modalities may be non conclusive and immuno-
histochemistry must be relied upon to make the final
definitive diagnosis. Metastatic presentation is more
common than primary ovarian melanoma and should be
suspected in any patient who presents a history of
malignant melanoma with an ovarian mass without
benign cystic teratomas, even if the remission period is
long and the ovary is the initial site of relapse. Surgical
interventions may be undertaken only in limited meta-
static disease, where complete resection is expected.
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